These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38616443)

  • 21. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
    Korde LA; Somerfield MR; Carey LA; Crews JR; Denduluri N; Hwang ES; Khan SA; Loibl S; Morris EA; Perez A; Regan MM; Spears PA; Sudheendra PK; Symmans WF; Yung RL; Harvey BE; Hershman DL
    J Clin Oncol; 2021 May; 39(13):1485-1505. PubMed ID: 33507815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
    Hofmann D; Nitz U; Gluz O; Kates RE; Schinkoethe T; Staib P; Harbeck N
    Trials; 2013 Aug; 14():261. PubMed ID: 23958221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
    Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
    Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy.
    Samiei S; van Nijnatten TJA; de Munck L; Keymeulen KBMI; Simons JM; Kooreman LFS; Siesling S; Lobbes MBI; Smidt ML
    Ann Surg; 2020 Mar; 271(3):574-580. PubMed ID: 30557203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
    Shao Y; Yu Y; Luo Z; Guan H; Zhu F; He Y; Chen Q; Liu C; Nie B; Liu H
    Ann Surg Oncol; 2022 Dec; 29(13):8026-8034. PubMed ID: 35933542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.
    Spring LM; Bar Y; Isakoff SJ
    J Natl Compr Canc Netw; 2022 Jun; 20(6):723-734. PubMed ID: 35714678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective.
    McGee SF; Clemons M; Savard MF
    Curr Oncol; 2022 Jun; 29(6):4125-4137. PubMed ID: 35735438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
    Golshan M; Loibl S; Wong SM; Houber JB; O'Shaughnessy J; Rugo HS; Wolmark N; McKee MD; Maag D; Sullivan DM; Metzger-Filho O; Von Minckwitz G; Geyer CE; Sikov WM; Untch M
    JAMA Surg; 2020 Mar; 155(3):e195410. PubMed ID: 31913413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).
    Houvenaeghel G; Lambaudie E; Cohen M; Classe JM; Reyal F; Garbay JR; Giard S; Chopin N; Martinez A; Rouzier R; Daraï E; Colombo PE; Coutant C; Gimbergues P; Azuar P; Villet R; Tunon de Lara C; Barranger E; Sabiani L; Goncalves A
    Breast; 2017 Aug; 34():24-33. PubMed ID: 28475932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.
    Shinde AM; Zhai J; Yu KW; Frankel P; Yim JH; Luu T; Kruper L; Vito C; Shaw S; Vora NL; Kirschenbaum M; Somlo G
    Breast; 2015 Feb; 24(1):18-23. PubMed ID: 25467313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Huo X; Li J; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    BMC Cancer; 2021 Jan; 21(1):78. PubMed ID: 33468087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
    Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
    Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
    Steenbruggen TG; van Seijen M; Janssen LM; van Ramshorst MS; van Werkhoven E; Vrancken Peeters MTDF; Wesseling J; Lips EH; Sonke GS
    Clin Cancer Res; 2019 Aug; 25(16):4985-4992. PubMed ID: 31076546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant or adjuvant chemotherapy in early breast cancer?
    Montemurro F; Nuzzolese I; Ponzone R
    Expert Opin Pharmacother; 2020 Jun; 21(9):1071-1082. PubMed ID: 32237920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer.
    Miglietta F; Dieci MV; Griguolo G; Guarneri V
    Cancer Treat Rev; 2021 Jul; 98():102222. PubMed ID: 34023642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant and Adjuvant Therapies for Breast Cancer.
    Apuri S
    South Med J; 2017 Oct; 110(10):638-642. PubMed ID: 28973704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
    Schlam I; Dower J; Lynce F
    Curr Oncol Rep; 2024 Apr; 26(4):336-345. PubMed ID: 38393609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.